Life SciencesLiability
Get a quote

TL;DR

Five biotech cyber tower structures by stage - pre-IND through commercial. Sizing scales with funding stage AND with the data categories actually held (IND data, clinical PHI, DMF trade secrets, commercial distribution data). The IPO-readiness stage is where the underwriter cyber audit stress-tests the program and where operators most often discover gaps.

Best of 2026

Biotech Cyber Insurance: 5 Tower Structures by Stage.

Biotech cyber insurance sizing follows funding stage AND the specific data categories the operator holds. The five structures below cover the typical biotech lifecycle from discovery through commercial launch, with the load-bearing endorsements and premium ranges for each.

  1. 01

    Pre-IND biotech

    Discovery and IND-enabling biotechs without an active clinical trial. Typically pre-revenue or first outside-investor round.

    • - $1M-$3M cyber tower as the baseline. Below $1M leaves drug master file (DMF) and platform-IP exposure unfunded.
    • - Trade secret extension wording for DMF and proprietary cell line content.
    • - Basic breach response and notification coverage.
    • - No clinical PHI exposure yet; HIPAA Business Associate coverage typically deferred until first CTA.
    • - Standard cyber form acceptable if endorsed for IND data category.

    Premium range: $8K-$25K annually.

  2. 02

    Phase 1 - Phase 2 clinical

    Biotechs with active CTAs and live clinical PHI handling. Typically Series A through Series C.

    • - $3M-$5M tower; multi-site international Phase 2 typically pushes to the upper end.
    • - HIPAA Business Associate coverage with explicit BA breach scope.
    • - Civil monetary penalty coverage under HITECH.
    • - Trade secret extension maintained for DMF and platform IP.
    • - Regulatory defense for the strictest applicable state privacy regime (CA CMIA/CCPA, CT, MD MOPDPA, WA MHMDA, TX TDPSA).
    • - Contingent cyber for CRO, eTMF, EDC, central lab vendor failures.

    Premium range: $15K-$40K annually.

  3. 03

    IPO-readiness

    Biotechs in the 12-18 months preceding an IPO, SPAC merger, or reverse merger. The underwriter cyber diligence stress-tests the program.

    • - $5M-$15M tower. IPO underwriter cyber diligence is materially stricter than pre-IPO operators expect.
    • - Coordination with D&O architecture - cyber-tied securities class action exposure is part of the IPO underwriter representation.
    • - SOC 2 Type II or ISO 27001 increasingly expected before placement.
    • - Incident response retainer with named forensic IR vendor.
    • - 24/7 SOC monitoring documentation required at the upper-tower end.
    • - Sponsor partnership PHI / DMF flow coverage formalized.

    Premium range: $30K-$80K annually.

  4. 04

    Post-IPO clinical-stage

    Public biotechs still in clinical development without commercial product. Public-company cyber expectations apply.

    • - $10M-$25M tower as the public-company baseline.
    • - SEC cybersecurity disclosure obligations under Item 1.05 of Form 8-K compliance built into the policy.
    • - Coordination with D&O for derivative securities class action exposure tied to cyber events.
    • - Heightened SOC monitoring, MFA enforcement, and zero-trust architecture documentation.
    • - Sponsor and CRO contractual cyber pass-through coverage.
    • - Regulatory defense scope covering HHS OCR, SEC, and FTC parallel inquiries.

    Premium range: $60K-$150K annually.

  5. 05

    Commercial-stage biotech

    Biotechs with at least one commercial product. Commercial distribution adds cyber exposures pre-commercial operators do not face.

    • - $15M-$50M+ tower. Multiple commercial products in oncology or rare disease push toward $50M-$100M.
    • - Patient assistance program (PAP) data coverage - PAPs handle PHI at scale.
    • - Direct-to-consumer marketing data coverage where applicable.
    • - Commercial distribution channel cyber - specialty pharmacy, hub services, hospital integration.
    • - Sales force device and BYOD coverage.
    • - M&A cyber due diligence representation coverage if acquisitive.

    Premium range: $150K-$500K+ annually depending on commercial scale.

Frequently asked

Common questions about biotech cyber insurance

How much biotech cyber insurance does a clinical-stage company need?

Sizing tracks funding stage AND data categories held. Pre-IND discovery operators baseline at $1M-$3M for drug master file and platform IP. Phase 1-2 biotechs holding clinical PHI baseline at $3M-$5M with explicit HIPAA Business Associate scope. IPO-readiness operators step up to $5M-$15M because the underwriter cyber diligence is materially stricter than pre-IPO operators expect. Post-IPO clinical-stage public biotech baselines at $10M-$25M to match public-company cyber expectations and SEC disclosure obligations under Item 1.05 of Form 8-K. Commercial-stage biotech with one or more approved products typically runs $15M-$50M+ depending on patient assistance program data, DTC marketing, and specialty pharmacy channel exposure.

When should a biotech buy cyber insurance?

At pre-IND once drug master file (DMF) and platform IP are written down. Below $1M of cyber leaves trade secret and DMF exposure unfunded, and most term sheets from institutional investors require cyber. Adding HIPAA Business Associate scope is typically deferred until the first clinical trial agreement is signed - that is when clinical PHI handling begins.

Does biotech cyber insurance cover ransomware on IND data?

Standard cyber forms cover IND data with the right endorsements: trade secret extension, regulatory defense for HHS OCR, and contingent business interruption from a clinical operations halt. Carriers that play in the life-sciences specialty cyber market know how to underwrite IND data. Generalist tech-startup cyber programs typically do not - the DMF and platform IP either fall outside trade secret scope or are sublimited.

How does biotech cyber insurance coordinate with D&O for IPO/SPAC?

Cyber-tied securities class actions are an explicit underwriting concern in the IPO/SPAC D&O placement. A cyber event followed by a stock drop can trigger a securities class action alleging inadequate disclosure of cyber risk. The cyber tower needs to coordinate with the D&O architecture so the regulatory defense scope, the SEC Form 8-K Item 1.05 disclosure response, and the derivative-suit exposure are all funded through compatible carriers. We size both at the same time during IPO-readiness placement.

What is the difference between biotech cyber insurance and general technology cyber insurance?

Biotech cyber is a specialty subset that adds: HIPAA Business Associate coverage with explicit BA breach scope; HITECH civil monetary penalty coverage; trade secret extension for drug master files and proprietary cell lines; state genetic privacy statute regulatory defense (CA CMIA/CCPA, WA MHMDA, MD MOPDPA, TX TDPSA); contingent cyber for CRO, eTMF, EDC, and central lab vendor failures; and IPO underwriter cyber audit alignment. A generalist tech-startup cyber policy will not contain most of these. The placement carriers active in the class are a narrow specialty set.

How much does biotech cyber insurance cost?

Premium ranges scale with stage and tower size: pre-IND $8K-$25K annually for a $1M-$3M tower; Phase 1-2 $15K-$40K for $3M-$5M; IPO-readiness $30K-$80K for $5M-$15M; post-IPO clinical-stage $60K-$150K for $10M-$25M; commercial-stage $150K-$500K+ for $15M-$50M+. The variables that drive cost most are: data category and volume (clinical PHI vs DMF only), prior incidents, SOC 2/ISO 27001 certification status, incident response retainer in place, and MFA/zero-trust documentation.

Biotech insurance practice →Biotech D&O architecture 2026 →Best cyber insurance for CROs 2026 →Cyber for biotech IPO readiness →Bay Area biotech cluster →Boston biotech cluster →

Biotech cyber review

A specialist will reach out by end of business day.

Request a coverage review